Studies in Paget's disease and their relevance to oncology
References (31)
- et al.
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton
Bone
(1998) Paget's disease and osteoclast biology
Bone
(1996)- et al.
Elevated levels of circulating interleukin-6 and transforming growthfactor-beta 1 in patients with metastatic prostatic carcinoma
J Urol
(1999) - et al.
Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma
Human Pathol
(1998) New insights into the role of the microenvironment in multiple myeloma
Lancet
(2000)- et al.
RANK is the essential signalling receptor for osteoclast differentiation factor in osteoclastogenesis
Biochem Biophys Res Commun
(1998) - et al.
Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro
Biochem Biophys Res Commun
(2000) - et al.
A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease
Am J Med
(1988) - et al.
Paget's disease of the bone: Reduction of disease activity with oral risedronate
Bone
(1998) - et al.
Markers of bone resorption in patients treated with pamidronate
Eur J Cancer
(1998)
Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D (3) and RANKL
Bone
Regulation of the differentiation and function of osteoclasts
J Pathol
Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of the bone
J Clin Invest
Breast cancer cells interact with osteoblasts to support osteoclast formation
Endocrinology
Bisphosphonates in the treatment of disorders of mineral metabolism
Adv Endocrinol Metab
Cited by (23)
RANKL-independent modulation of osteoclastogenesis
2019, Journal of Oral BiosciencesCitation Excerpt :These results suggest that IL-1RI expression is the most critical prerequisite for osteoclasts or precursors to respond to IL-1. IL-6 is a pro-inflammatory cytokine that has been implicated in diseases associated with bone loss, such as postmenopausal osteoporosis, rheumatoid arthritis, and Paget's disease [46,47]. IL-6 can indirectly promote osteoclast formation and activation by inducing RANKL production in osteoblastic/stromal cells [48,49].
Prevention and management of bone metastases in lung cancer a review
2009, Journal of Thoracic OncologyCitation Excerpt :Bisphosphonates are a group of compounds that are stable analogues of naturally occurring inorganic pyrophosphate. When bound to hydroxyapatite, they are specific inhibitors of osteoclast activity and this subsequently leads to inhibition of bone resorption.40–42 The most commonly investigated bisphosphonates in cancer are the first-generation compound clodronate (Bonefos; Schering AG, Berlin, Germany), second-generation pamidronate (Aredia; Novartis Pharmaceuticals Corporation, East Hanover, NJ), third-generation zoledronic acid (Zometa; Novartis Pharma Stein AG, Stein, Switzerland), and third-generation ibandronate (Boniva; Roche Laboratories Inc., Nutley, NJ).
P
2007, Geriatric Clinical AdvisorP
2006, Geriatric Clinical Advisor: Instant Diagnosis and Treatment, Book, WebsiteThe neuropeptide VIP potentiates IL-6 production induced by proinflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1
2005, Biochemical and Biophysical Research Communications
- 1
Dr Roodman has served on the speakers' bureau for Novartis.